Search Results for "Amitiza And Dulcolax"
Original Source: A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment for Bowel Cleansing Prior to Colonoscopy
Miralax (PEG 3350) has been shown to be a safe and uncomplicated bowel preparation prior to colonoscopy in pediatric populations. This study seeks to confirm the efficacy of this bowel cleansing regimen in adults and to determine the benefit of adding a pretreatment medication to this bowel preparation. The tolerability of Miralax will hopefully improve patient satisfaction with colonoscopy and decrease their reluctance to be screened because of the uncomfortable taste and side...
Matching Channels
Laxatives are medicines that relieve constipation (difficulty with bowel movements). They are a popular type of over-the-counter remedy. They can also be prescribed for conditions that could get wor...
The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...
Matching News
AMITIZA for treatment of chronic constipation now available in Japan
Sucampo Pharmaceuticals, Inc. and Abbott today announced the availability of AMITIZA (lubiprostone) in Japan, a prescription medicine for the treatment of chronic constipation not caused by organic di...
Sucampo gets new priority review for Amitiza
Sucampo Pharmaceuticals Inc. said Tuesday the Food and Drug Administration agreed to conduct a faster review of its drug Amitiza as a treatment for constipation caused by opioid pain drugs.Sucampo an...
Sucampo falls as FDA extends Amitiza review
Sucampo Pharmaceuticals Inc. said Friday that regulators extended a new review of its constipation drug Amitiza.Sucampo and its partner, Japanese drugmaker Takeda, want the Food and Drug Administrati...
Sucampo Pharmaceuticals, Inc. ("Sucampo") (NASDAQ: SCMP) gab heute bekannt, dass die britische Arzneimittelbehörde AMITIZA® (Lubiproston) zugelassen hat. Das Medikament wird in einer zweimal tägli....
Sucampo Pharma, Abbott Launch AMITIZA In Japan
NORTH CHICAGO (dpa-AFX) - Sucampo Pharmaceuticals Inc. (SCMP) and Abbott (ABT) announced the availability of AMITIZA in Japan, a prescription medicine for the treatment of chronic constipation not...
Sucampo must live with Takeda as Amitiza arbitration fails to go its way
Sucampo Pharmaceuticals' loss of an arbitration decision relating to a key partnership for its main commercial product Amitiza (lubiprostone) means that, like it or not, it will have to continue work...
Sucampo und Abbott melden Einführung von AMITIZA in Japan
Japans einziges rezeptpflichtiges Präparat bei chronischer Obstipation Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) und Abbott (NYSE: ABT) gaben heute bekannt, dass AMITIZA® (Lubiproston), e.....
Sucampo/Takeda drug Amitiza wins 1st FDA nod in OIC non-cancer pain
Sucampo Pharmaceuticals and its partner Takeda won the US FDA's blessing on 23 April to market Amitiza (lubiprostone) 24mcg twice daily as the first and only oral medicine to treat opioid-induced c...
Matching PubMed Articles
Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease.
To evaluate the efficacy and tolerability of lubiprostone (Amitiza) for constipation in Parkinson disease (PD) in a double-blind, randomized, controlled study.
Lubiprostone for the Treatment of Adults with Constipation and Irritable Bowel Syndrome.
Chronic constipation and IBS-C are two of the most common functional bowel disorders encountered by primary care providers and gastroenterologists, affecting up to 27% of the population in Western cou...
